DK3464305T3 - Fremgangsmåder til fremstilling af oligomerer - Google Patents

Fremgangsmåder til fremstilling af oligomerer Download PDF

Info

Publication number
DK3464305T3
DK3464305T3 DK17731336.8T DK17731336T DK3464305T3 DK 3464305 T3 DK3464305 T3 DK 3464305T3 DK 17731336 T DK17731336 T DK 17731336T DK 3464305 T3 DK3464305 T3 DK 3464305T3
Authority
DK
Denmark
Prior art keywords
oligomers
processes
production
Prior art date
Application number
DK17731336.8T
Other languages
English (en)
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Diane Elizabeth Frank
Richard K Bestwick
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Application granted granted Critical
Publication of DK3464305T3 publication Critical patent/DK3464305T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
DK17731336.8T 2016-05-24 2017-05-24 Fremgangsmåder til fremstilling af oligomerer DK3464305T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662356923P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201662357166P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/034235 WO2017205496A1 (en) 2016-05-24 2017-05-24 Processes for preparing oligomers

Publications (1)

Publication Number Publication Date
DK3464305T3 true DK3464305T3 (da) 2024-10-28

Family

ID=59078165

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17731336.8T DK3464305T3 (da) 2016-05-24 2017-05-24 Fremgangsmåder til fremstilling af oligomerer

Country Status (21)

Country Link
US (2) US10875880B2 (da)
EP (2) EP3564248A1 (da)
JP (2) JP7008642B2 (da)
KR (1) KR102506298B1 (da)
CN (1) CN109563114B (da)
AU (1) AU2017269355B2 (da)
BR (2) BR112018074346B1 (da)
CA (1) CA3025339A1 (da)
CO (1) CO2018013838A2 (da)
DK (1) DK3464305T3 (da)
ES (1) ES2993738T3 (da)
FI (1) FI3464305T3 (da)
HR (1) HRP20241428T1 (da)
IL (1) IL263149B2 (da)
MA (2) MA49775A (da)
MD (1) MD3464305T2 (da)
MX (2) MX384727B (da)
SA (1) SA518400500B1 (da)
SG (1) SG10202101830WA (da)
TW (2) TWI801843B (da)
WO (1) WO2017205496A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA49775A (fr) 2016-05-24 2020-06-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
KR102523522B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
EP3672601B1 (en) * 2017-09-25 2023-09-13 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
EP3784248A4 (en) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
EP4658280A2 (en) * 2023-02-01 2025-12-10 Alnylam Pharmaceuticals, Inc. Six membered ring containing oligomers

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0433345B1 (en) 1988-09-01 1994-04-20 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
AU694157B2 (en) 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004043978A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
DK2735568T3 (da) * 2006-05-10 2017-11-13 Sarepta Therapeutics Inc Oligonukleotidanaloger med kationiske bindinger mellem underenheder
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CN112574988A (zh) 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
LT2499249T (lt) 2009-11-12 2018-12-27 The University Of Western Australia Priešprasmės molekulės ir patologijų gydymo būdai
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
EP2672977A1 (en) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
WO2013026142A1 (en) 2011-08-23 2013-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
ES2727481T3 (es) * 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
CN117721110A (zh) * 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
US9670529B2 (en) 2012-02-28 2017-06-06 Population Genetics Technologies Ltd. Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
NZ731587A (en) 2013-03-14 2021-07-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
RS58529B1 (sr) 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
WO2014189142A1 (ja) 2013-05-24 2014-11-27 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA49775A (fr) 2016-05-24 2020-06-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
SI3554554T1 (sl) 2016-12-19 2023-02-28 Sarepta Therapeutics, Inc. Oligomerni konjugati, ki preskakujejo ekson za mišično distrofijo
SMT202200366T1 (it) 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
IL297528A (en) 2016-12-19 2022-12-01 Sarepta Therapeutics Inc Exon-skipping oligomer conjugates for muscular dystrophy
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
MX2018014472A (es) 2019-05-23
CA3025339A1 (en) 2017-11-30
FI3464305T3 (fi) 2024-10-30
BR112018074346B1 (pt) 2023-01-03
TWI801843B (zh) 2023-05-11
US11384105B2 (en) 2022-07-12
EP3564248A1 (en) 2019-11-06
BR112018074346A2 (pt) 2019-03-06
HRP20241428T1 (hr) 2025-01-03
ES2993738T3 (en) 2025-01-08
AU2017269355B2 (en) 2021-04-15
SA518400500B1 (ar) 2022-09-01
CN109563114B (zh) 2022-08-12
US10875880B2 (en) 2020-12-29
US20210198296A1 (en) 2021-07-01
JP2019518832A (ja) 2019-07-04
AU2017269355A1 (en) 2019-01-17
BR122022014984B1 (pt) 2024-03-05
TW202200599A (zh) 2022-01-01
MA45154A (fr) 2019-04-10
IL263149A (en) 2019-01-31
JP2021176967A (ja) 2021-11-11
TWI738784B (zh) 2021-09-11
MD3464305T2 (ro) 2025-01-31
WO2017205496A1 (en) 2017-11-30
MA49775A (fr) 2020-06-10
CO2018013838A2 (es) 2019-01-18
IL263149B1 (en) 2023-01-01
IL263149B2 (en) 2023-05-01
JP7008642B2 (ja) 2022-01-25
SG10202101830WA (en) 2021-04-29
TW201806962A (zh) 2018-03-01
CN109563114A (zh) 2019-04-02
EP3464305A1 (en) 2019-04-10
MX384727B (es) 2025-03-14
MA45154B1 (fr) 2024-11-29
US20200040020A1 (en) 2020-02-06
KR102506298B1 (ko) 2023-03-06
MX2021008539A (es) 2022-10-18
KR20190015311A (ko) 2019-02-13
EP3464305B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
IL264143B (en) Processes for preparing olaparib
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3464305T3 (da) Fremgangsmåder til fremstilling af oligomerer
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3377201T3 (da) Fremgangsmåde til fremstilling af membraner
DK3464306T3 (da) Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
DK3294865T3 (da) Fremgangsmåder til fremstilling af epimeraser og benzylisoquinolinalkaloider
DK3312270T3 (da) Fremgangsmåde til fremstilling af plader med høj ydeevne
HUE055744T2 (hu) Eljárás pszikóz fruktóz-tartalmú szubsztrátból
DK3166904T3 (da) Fremgangsmåde til fremstilling af betonelementer
DK3416936T3 (da) Fremgangsmåde til fremstilling af methanol
DK3359522T3 (da) Proces til fremstilling af N-Boc-bifenylalaninol
DK3218396T3 (da) Fremgangsmåde til fremstilling af højaffinitets antistoffer
DK3261661T3 (da) Menotropin til behandling af infertilitet
HUE053818T2 (hu) Eljárás HMF elõállítására
DK3481811T3 (da) Industriel fremgangsmåde til forberedelse af cariprazin
DK3443110T3 (da) Fermenteringsproces til fremstilling af maltosyl-isomalto-oligosaccharider (mimo)
DK3166923T3 (da) Fremgangsmåde til fremstilling af substituerede phenylalkaner
DK3490938T3 (da) Fremgangsmåder til dannelse af titancatecholkomplekser
DK3495339T3 (da) Fremgangsmåde til fremstilling af reaktionsprodukt
HUE044577T2 (hu) Eljárás karbamid elõállítására
DK3286209T3 (da) Fremgangsmåde til fremstilling af gonadotrophin
DK3259364T3 (da) Fremgangsmåder til styring af proteasefremstilling
DK3592723T3 (da) Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en
EP3523659C0 (en) MULTI-PROTEASE PROCESS